Prostate Cancer
Conference Coverage
‘Treatment holiday’ in prostate cancer with tailored dosing
“Personalizing dosing intervals using early-response biomarkers with 177Lu-PSMA has the potential to achieve similar overall treatment...
Article
Cancer Data Trends 2023
News
Risk of falls seen with newer antiandrogens for prostate cancer
The take-home message is that the findings give men – and the physicians who counsel them – a fuller idea of what to expect when considering using...
Commentary
COVID can mimic prostate cancer symptoms
“I had none of those previously reported experiences that could suddenly trigger a spike in PSA.”
Conference Coverage
Plant-based diet linked to better outcomes in prostate cancer
Men who consumed more fruits and vegetables had slower cancer progression and lower risk of recurrence.
Conference Coverage
Prostate cancer subgroup may benefit from intensified therapy
A new trial explored whether for patients with prostate cancer who have unfavorable features and a detectable PSA following a radical...
Conference Coverage
Talazoparib add-on improves outcomes in metastatic prostate cancer
As determined on the basis of imaging, PFS was 37% better for talazoparib plus enzalutamide than for enzalutamide monotherapy.
Conference Coverage
Rucaparib benefit in BRCA+ prostate cancer confirmed
New study finding provides evidence of clinical benefit for an indication for rucaparib that was granted an accelerated approval in May 2020.
Conference Coverage
Colorectal cancer treatment outcomes in older adults
Disease-free survival boosted by adjuvant therapy completion, but only about half of patients finish.
News
New cancer data spark outcry from patient advocates
The American Cancer Society on Jan. 13 revealed what it called ‘alarming’ news about prostate cancer.
